ROG has been the subject of a number of other research reports. Deutsche Bank set a CHF 255 price objective on shares of Roche and gave the company a neutral rating in a research report on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on shares of Roche and gave the company a neutral rating in a research report on Tuesday, October 24th. JPMorgan Chase & Co. reissued a buy rating on shares of Roche in a research report on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on shares of Roche and gave the company a neutral rating in a research report on Friday, October 6th. Finally, Jefferies Group set a CHF 295 price objective on shares of Roche and gave the company a buy rating in a research report on Monday, October 16th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of CHF 262.37.
Roche (ROG) opened at CHF 247.70 on Wednesday. Roche has a 12-month low of CHF 226.10 and a 12-month high of CHF 273. The company has a market cap of $213,200.00 and a PE ratio of 22.02.
TRADEMARK VIOLATION WARNING: “Roche (ROG) Receives Buy Rating from Nord/LB” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/28/roche-rog-receives-buy-rating-from-nordlb.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
What are top analysts saying about Roche? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Roche and related companies.